Previous 10 | Next 10 |
CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
Shares of Mersana Therapeutics are up 21% in 2022 and +168% over the past 3 years. Management sees lead antibody drug conjugate UpRi gaining broad use in ovarian cancer, though I remain skeptical. GSK partnership in HER2 was wise, considering high competition in this space. B7...
Gainers: BBQ Holdings ( BBQ ) +46% . Verona Pharma ( VRNA ) +41% . Mersana Therapeutics ( MRSN ) +31% . SAI.TECH Global ( SAI ) +30% . Atara Biotherapeutics ( ATRA ) +28% . PubMatic ( PUBM ) +24% . RumbleON ( RM...
Mersana Therapeutics ( MRSN ) stock rose +36% on Aug. 9 following a collaboration agreement with GSK ( GSK ) for XMT-2056. Under the agreement, Mersana granted GSK exclusive option to co-develop and commercialize XMT-2056, an antibody-drug conjugate for use against ...
Gainers: Verona Pharma VRNA +87% . Mersana Therapeutics ( MRSN ) +38% . GoodRx Holdings ( GDRX ) +19% . Atara Biotherapeutics ( ATRA ) +22% . Heron Therapeutics HRTX +16% . Losers: CorMedix ( CRMD ) -56% . Qu...
Mersana Therapeutics, Inc. (MRSN) Q2 2022 Earnings Conference Call August 08, 2022 04:30 PM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications Anna Protopapas - President, CEO & Director Arvin Yang ...
The following slide deck was published by Mersana Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Mersana Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation
Mersana Therapeutics press release ( NASDAQ: MRSN ): Q2 GAAP EPS of -$0.55 misses by $0.03 . Revenue of $4.28M beats by $2.08M . For further details see: Mersana Therapeutics GAAP EPS of -$0.55 misses by $0.03, revenue of $4.28M beats by $2.08M
Approaching full enrollment in UPLIFT clinical trial; initiated patient screening in UP-NEXT clinical trial Cleared INDs for XMT-1660 and XMT-2056 Enhanced balance sheet with $100 million upfront option purchase fee to be paid by GSK for XMT-2056 Conference call ...
GSK receives exclusive global license option for XMT-2056 Mersana to receive $100 million upfront option purchase fee If GSK exercises its option, Mersana to receive exercise payment; potential for additional development, regulatory and commercial milestone payments, plu...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...